{"title":"比较阿立哌唑加用丙戊酸钠与其他第二代抗精神病药物治疗伊朗躁狂患者急性躁狂症状的疗效","authors":"Zeinab Sadat Ayatollahi, Mehran Shayganfard, Hamidreza Jamilian, Anita Alaghmand","doi":"10.1080/13651501.2022.2030758","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Given the great importance of treating patients with bipolar disorder, the aim of this study was to compare the efficacy of aripiprazole with other second-generation antipsychotics in relieving acute symptoms of mania.</p><p><strong>Materials and methods: </strong>In this study, 50 patients with bipolar I disorder, manic episode, were divided into two groups receiving aripiprazole (<i>n</i> = 25) and other second-generation antipsychotics (risperidone, olanzapine, and quetiapine) (<i>n</i> = 25) for 6 weeks. The disease severity was evaluated and compared according to YMRS and CGI criteria.</p><p><strong>Results: </strong>The mean severity of mania according to YMRS and CGI, at week 0 in comparison with weeks 2, 4 and 6 in both groups was significantly different (<i>p</i> < 0.0001) and the treatment with Aripiprazole at week 2 (<i>p</i> < 0.0001) and 4 (<i>p</i> = 0.0002) was significantly better than the other second-generation antipsychotics. The two groups also showed an overall improvement in CGI-based results at weeks 4 and 6 (<i>p</i> = 0.002). In addition, the efficacy index for aripiprazole at weeks 4 (<i>p</i> = 0.011) and 6 (<i>p</i> < 0.0001) as well as disease improvement in the second (<i>p</i> < 0.0001) and fourth (<i>p</i> = 0.026) weeks after treatment were better than the other second-generation antipsychotics.</p><p><strong>Conclusions: </strong>Aripiprazole and other second-generation antipsychotics, 2 weeks after initiation of treatment, significantly reduced mania severity in patients with bipolar disorder, however, aripiprazole seems to be more efficient and faster for controlling mania in patients with bipolar disorder.KEY POINTSAripiprazole and other second-generation antipsychotics, 2 weeks after initiation of treatment, significantly reduced mania severity in patients with bipolar disorder.Comparison between the two drugs, aripiprazole showed a more beneficial role in the second and fourth weeks than second-generation antipsychotics.Due to the fact that the possible mechanisms involved in the role of aripiprazole have not been considered compared to other antipsychotics in patients with bipolar disorder, there is a need for more extensive studies in this field.</p>","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparing the efficacy of aripiprazole as an add-on to valproate with other second-generation antipsychotics in acute mania symptoms in manic patients in Iran.\",\"authors\":\"Zeinab Sadat Ayatollahi, Mehran Shayganfard, Hamidreza Jamilian, Anita Alaghmand\",\"doi\":\"10.1080/13651501.2022.2030758\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Given the great importance of treating patients with bipolar disorder, the aim of this study was to compare the efficacy of aripiprazole with other second-generation antipsychotics in relieving acute symptoms of mania.</p><p><strong>Materials and methods: </strong>In this study, 50 patients with bipolar I disorder, manic episode, were divided into two groups receiving aripiprazole (<i>n</i> = 25) and other second-generation antipsychotics (risperidone, olanzapine, and quetiapine) (<i>n</i> = 25) for 6 weeks. The disease severity was evaluated and compared according to YMRS and CGI criteria.</p><p><strong>Results: </strong>The mean severity of mania according to YMRS and CGI, at week 0 in comparison with weeks 2, 4 and 6 in both groups was significantly different (<i>p</i> < 0.0001) and the treatment with Aripiprazole at week 2 (<i>p</i> < 0.0001) and 4 (<i>p</i> = 0.0002) was significantly better than the other second-generation antipsychotics. The two groups also showed an overall improvement in CGI-based results at weeks 4 and 6 (<i>p</i> = 0.002). In addition, the efficacy index for aripiprazole at weeks 4 (<i>p</i> = 0.011) and 6 (<i>p</i> < 0.0001) as well as disease improvement in the second (<i>p</i> < 0.0001) and fourth (<i>p</i> = 0.026) weeks after treatment were better than the other second-generation antipsychotics.</p><p><strong>Conclusions: </strong>Aripiprazole and other second-generation antipsychotics, 2 weeks after initiation of treatment, significantly reduced mania severity in patients with bipolar disorder, however, aripiprazole seems to be more efficient and faster for controlling mania in patients with bipolar disorder.KEY POINTSAripiprazole and other second-generation antipsychotics, 2 weeks after initiation of treatment, significantly reduced mania severity in patients with bipolar disorder.Comparison between the two drugs, aripiprazole showed a more beneficial role in the second and fourth weeks than second-generation antipsychotics.Due to the fact that the possible mechanisms involved in the role of aripiprazole have not been considered compared to other antipsychotics in patients with bipolar disorder, there is a need for more extensive studies in this field.</p>\",\"PeriodicalId\":14351,\"journal\":{\"name\":\"International Journal of Psychiatry in Clinical Practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Psychiatry in Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13651501.2022.2030758\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2022.2030758","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
摘要
背景:鉴于治疗双相情感障碍患者的重要性，本研究的目的是比较阿立哌唑与其他第二代抗精神病药物在缓解躁狂急性症状方面的疗效。材料与方法:本研究将50例躁狂期双相I型障碍患者分为两组，分别给予阿立哌唑(n = 25)和其他第二代抗精神病药物(利培酮、奥氮平、喹硫平)治疗6周。根据YMRS和CGI标准对疾病严重程度进行评价和比较。结果:根据YMRS和CGI的平均躁狂严重程度，在第0周与第2、4、6周比较，两组均有显著差异(p p p = 0.0002)，显著优于其他二代抗精神病药物。两组在第4周和第6周的cgi结果也显示出总体改善(p = 0.002)。阿立哌唑治疗后第4周(p = 0.011)、第6周(p = 0.026)疗效指标优于其他二代抗精神病药物。结论:阿立哌唑与其他第二代抗精神病药物在开始治疗2周后可显著降低双相情感障碍患者躁狂严重程度，但阿立哌唑对双相情感障碍患者躁狂的控制似乎更有效、更快。阿立哌唑和其他第二代抗精神病药物，在开始治疗2周后，显著降低双相情感障碍患者的躁狂症严重程度。两种药物比较，阿立哌唑在第2周和第4周表现出比第二代抗精神病药物更有利的作用。由于与其他抗精神病药物相比，阿立哌唑在双相情感障碍患者中的作用可能涉及的机制尚未得到考虑，因此需要在这一领域进行更广泛的研究。
Comparing the efficacy of aripiprazole as an add-on to valproate with other second-generation antipsychotics in acute mania symptoms in manic patients in Iran.
Background: Given the great importance of treating patients with bipolar disorder, the aim of this study was to compare the efficacy of aripiprazole with other second-generation antipsychotics in relieving acute symptoms of mania.
Materials and methods: In this study, 50 patients with bipolar I disorder, manic episode, were divided into two groups receiving aripiprazole (n = 25) and other second-generation antipsychotics (risperidone, olanzapine, and quetiapine) (n = 25) for 6 weeks. The disease severity was evaluated and compared according to YMRS and CGI criteria.
Results: The mean severity of mania according to YMRS and CGI, at week 0 in comparison with weeks 2, 4 and 6 in both groups was significantly different (p < 0.0001) and the treatment with Aripiprazole at week 2 (p < 0.0001) and 4 (p = 0.0002) was significantly better than the other second-generation antipsychotics. The two groups also showed an overall improvement in CGI-based results at weeks 4 and 6 (p = 0.002). In addition, the efficacy index for aripiprazole at weeks 4 (p = 0.011) and 6 (p < 0.0001) as well as disease improvement in the second (p < 0.0001) and fourth (p = 0.026) weeks after treatment were better than the other second-generation antipsychotics.
Conclusions: Aripiprazole and other second-generation antipsychotics, 2 weeks after initiation of treatment, significantly reduced mania severity in patients with bipolar disorder, however, aripiprazole seems to be more efficient and faster for controlling mania in patients with bipolar disorder.KEY POINTSAripiprazole and other second-generation antipsychotics, 2 weeks after initiation of treatment, significantly reduced mania severity in patients with bipolar disorder.Comparison between the two drugs, aripiprazole showed a more beneficial role in the second and fourth weeks than second-generation antipsychotics.Due to the fact that the possible mechanisms involved in the role of aripiprazole have not been considered compared to other antipsychotics in patients with bipolar disorder, there is a need for more extensive studies in this field.
期刊介绍：
International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry.
The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice.
Focus on the practical aspects of managing and treating patients.
Essential reading for the busy psychiatrist, trainee and interested physician.
Includes original research papers, comprehensive review articles and short communications.
Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
